This program focuses on crucial aspects including therapy adherence, personalised diet counselling, medication assistance, and tailored lifestyle modifications, all overseen by healthcare professionals.
Global pharmaceutical company Lupin Limited (Lupin) has introduced Humrahi, a patient support program to help patients in diabetes management, focusing on adherence, behaviour, and transformation.
India bears the highest burden of diabetes globally, with an estimated 77 million individuals currently affected by the condition and a projected surge to 134 million cases by 2045. This alarming rise underscores the urgent need for innovative healthcare solutions.
Diabetes elevates the risk of various complications, including heart disease, stroke, kidney ailments, nerve damage, and vision impairment. Instances of diabetes, pre-diabetes, and hypertension have witnessed an alarming increase in the Asian subcontinent, underscoring the urgency of addressing this issue. However, effective disease management can significantly mitigate these risks.
Rajeev Sibal, president of India Region Formulations, Lupin, emphasised the gravity of the diabetes epidemic in India, dubbing the country as the global diabetes capital.
He said, "With Humrahi, our commitment is to provide patients with comprehensive support, from raising awareness about the disease to ensuring treatment adherence. We are committed to extending the benefits of Humrahi to every diabetic patient in India, serving as their dedicated partners on their journey towards better health and well-being."
The name '˜Humrahi' translates to '˜Companion,' signifying its role as a guiding partner in the journey of diabetes management. This program offers comprehensive support by placing a strong emphasis on critical aspects such as therapy adherence.
It includes personalised diet counselling, medication assistance, and tailored lifestyle modifications, all overseen by healthcare professionals. Moreover, Humrahi equips patients with the knowledge and skills necessary for precise insulin injection techniques, helping them to effectively manage their blood sugar levels and enhance their overall quality of life.
Patients can access the program through the Play Store or the App Store, as well as by visiting the dedicated website. Additionally, individuals seeking personalised assistance can connect with a dedicated care executive via the toll-free number available on the website.
Lupin is an innovation-driven global pharmaceutical company headquartered in Mumbai, India. The company specialises in the development and commercialisation of a wide range of branded and generic formulations, biotechnology products, and APIs (Active Pharmaceutical Ingredients).
India has encountered a staggering surge in diabetes cases in recent years, painting a pressing need for innovative solutions.
In a similar development, in response to the mounting diabetes challenges in India, Predictmedix AI, known for its global AI-driven diagnostics, recently unveiled a non-invasive diabetes screening method.
This advanced screening technique holds the capacity to identify early indicators of diabetes by analysing subtle biological markers that often elude traditional diagnostic methods.
Likewise, scientists at BITS Pilani, a leading institute of higher education, developed a portable system device to detect diabetes. It uses 3D printing technology that helps analyse and evaluate glucose and lactate levels in the body through sweat samples.